HCM:NSD-HUTCHMED DRC (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 17.04

Change

-0.44 (-2.52)%

Market Cap

USD 3.18B

Volume

0.07M

Analyst Target

USD 35.28
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

+0.07 (+0.54%)

USD 13.87B
NBIX Neurocrine Biosciences Inc

-1.50 (-1.18%)

USD 12.37B
ITCI Intracellular Th

-0.27 (-0.31%)

USD 9.17B
LNTH Lantheus Holdings Inc

-5.39 (-6.33%)

USD 7.63B
ALKS Alkermes Plc

+0.01 (+0.03%)

USD 4.73B
ALVO Alvotech

-0.23 (-1.89%)

USD 3.67B
AMPH Amphastar P

-2.23 (-4.67%)

USD 2.29B
SUPN Supernus Pharmaceuticals Inc

-0.06 (-0.16%)

USD 1.93B
HROW Harrow Health Inc

+1.89 (+3.79%)

USD 1.86B
KNSA Kiniksa Pharmaceuticals Ltd

-0.37 (-1.61%)

USD 1.59B

ETFs Containing HCM

CNCR Loncar Cancer Immunothera.. 1.65 % 0.79 %

-0.29 (-0.80%)

USD 0.01B
AVEE American Century ETF Trus.. 0.37 % 0.00 %

-0.44 (-0.80%)

USD 0.03B
AXJV 0.00 % 0.35 %

N/A

N/A
ECNS iShares MSCI China Small-.. 0.00 % 0.59 %

-0.12 (-0.80%)

USD 0.06B
IPOS Renaissance International.. 0.00 % 0.80 %

-0.11 (-0.80%)

N/A
CHNA 0.00 % 0.62 %

N/A

N/A
CHNA 0.00 % 0.79 %

N/A

N/A
MCHS Matthews China Discovery .. 0.00 % 0.00 %

-0.25 (-0.80%)

USD 4.44M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.91% 55% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.91% 55% F 39% F
Trailing 12 Months  
Capital Gain -8.93% 48% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.93% 48% F 32% F
Trailing 5 Years  
Capital Gain -26.80% 57% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.80% 57% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain 2.47% 49% F 46% F
Dividend Return 2.47% 49% F 42% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.41% 64% D 43% F
Risk Adjusted Return 5.69% 49% F 39% F
Market Capitalization 3.18B 91% A- 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.